Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T Symonds

Showing results (31-40 of 70) with videos related to

Pageof 7
Sort By:
The Annals of Pharmacotherapy|June 1, 1997
Assessment of the enzymuria resulting from gentamicin alone and combinations of gentamicin with various beta-lactam antibioticsD E Nix, J K Thomas, W T Symonds, et al.
The New England Journal of Medicine|January 4, 2013
Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis CEdward J Gane, Catherine A Stedman, Robert H Hyland, et al.
Industrial & Engineering Chemistry Research|September 2, 2025
Process Safety Considerations in the Design and Scale-Up of Chemical Looping ProcessesAndrew J Furlong, Nicole K Bond, Scott Champagne, et al.
Journal of Viral Hepatitis|September 10, 2013
All-oral therapy with nucleotide inhibitors sofosbuvir and GS-0938 for 14 days in treatment-naive genotype 1 hepatitis C (nuclear)E J Lawitz, M Rodriguez-Torres, J Denning, et al.
Hepatology (Baltimore, Md.)|October 18, 2014
Sofosbuvir with peginterferon-ribavirin for 12 weeks in previously treated patients with hepatitis C genotype 2 or 3 and cirrhosisEric Lawitz, Fred Poordad, Diana M Brainard, et al.
Lancet (London, England)|November 12, 2013
Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trialEric Lawitz, Fred F Poordad, Phillip S Pang, et al.
Antimicrobial Agents and Chemotherapy|March 18, 2000
Pharmacokinetic interaction between amprenavir and clarithromycin in healthy male volunteersD F Brophy, D S Israel, A Pastor, et al.
Pharmacotherapy|December 22, 1999
Pharmacokinetic interaction between ketoconazole and amprenavir after single doses in healthy menR E Polk, M A Crouch, D S Israel, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|January 27, 2015
Sofosbuvir for chronic hepatitis C virus infection genotype 1-4 in patients coinfected with HIVMaribel Rodriguez-Torres, Anuj Gaggar, Gong Shen, et al.
Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation|January 5, 2008
The impact of measuring patient-reported outcomes in clinical practice: a systematic review of the literatureJ M Valderas, A Kotzeva, M Espallargues, et al.
Pageof 7

Showing results (31-40 of 70) with videos related to

Sort By:
Pageof 7
The Annals of Pharmacotherapy|June 1, 1997
Assessment of the enzymuria resulting from gentamicin alone and combinations of gentamicin with various beta-lactam antibioticsD E Nix, J K Thomas, W T Symonds, et al.
The New England Journal of Medicine|January 4, 2013
Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis CEdward J Gane, Catherine A Stedman, Robert H Hyland, et al.
Industrial & Engineering Chemistry Research|September 2, 2025
Process Safety Considerations in the Design and Scale-Up of Chemical Looping ProcessesAndrew J Furlong, Nicole K Bond, Scott Champagne, et al.
Journal of Viral Hepatitis|September 10, 2013
All-oral therapy with nucleotide inhibitors sofosbuvir and GS-0938 for 14 days in treatment-naive genotype 1 hepatitis C (nuclear)E J Lawitz, M Rodriguez-Torres, J Denning, et al.
Hepatology (Baltimore, Md.)|October 18, 2014
Sofosbuvir with peginterferon-ribavirin for 12 weeks in previously treated patients with hepatitis C genotype 2 or 3 and cirrhosisEric Lawitz, Fred Poordad, Diana M Brainard, et al.
Lancet (London, England)|November 12, 2013
Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trialEric Lawitz, Fred F Poordad, Phillip S Pang, et al.
Antimicrobial Agents and Chemotherapy|March 18, 2000
Pharmacokinetic interaction between amprenavir and clarithromycin in healthy male volunteersD F Brophy, D S Israel, A Pastor, et al.
Pharmacotherapy|December 22, 1999
Pharmacokinetic interaction between ketoconazole and amprenavir after single doses in healthy menR E Polk, M A Crouch, D S Israel, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|January 27, 2015
Sofosbuvir for chronic hepatitis C virus infection genotype 1-4 in patients coinfected with HIVMaribel Rodriguez-Torres, Anuj Gaggar, Gong Shen, et al.
Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation|January 5, 2008
The impact of measuring patient-reported outcomes in clinical practice: a systematic review of the literatureJ M Valderas, A Kotzeva, M Espallargues, et al.
Pageof 7